Overview

Phase III ALTU-135 CP Safety Trial

Status:
Terminated

Trial end date:
2009-03-01

Target enrollment:

Participant gender:

Summary

This is an open-label, single-arm clinical study investigating the long-term safety of ALTU-135 treatment in Chronic Pancreatitis (CP) patients with exocrine Pancreatic Insufficiency (PI).

Phase:

Phase 3

Details

Lead Sponsor:

Anthera Pharmaceuticals